Effects in vitro of new growth hormone releasing peptide (GHRP-1) on growth hormone secretion from ovine pituitary cells in primary culture.

Wu D, Chen C, Zhang J, Katoh K, Clarke I

Journal of neuroendocrinology1 Apr 1994Cited by 18 (Europe PMC)

PMID8049717DOI10.1111/j.1365-2826.1994.tb00571.xPepBankPUB-08049717

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. No result from this study comes from people.

01LabIn vitro (cells)Mechanism
In ovine pituitary cells, GHRP‑6 increased GH secretion dose-dependently.
In plain wordsIn cells from sheep, GHRP‑6 increased growth hormone release in a dose-dependent manner.
Peptide
GHRP-6
Outcome
IncreaseGH release dose response
Study
sheepn: not reported in source
primary pituitary cells
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
GH was continuously released at a constant rate during perifusion and secretion was increased by KP 101, GHRP-6 and GRF in a dose-dependent manner.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971701
02LabIn vitro (cells)Mechanism
In ovine pituitary cells, the half-maximal effective GHRP‑6 dose was 10(-7) M, an order of magnitude above GRF.
In plain wordsIn cells from sheep, GHRP‑6 required a higher concentration than GRF for a half-maximal effect.
Peptide
GHRP-6
Outcome
Not applicableHalf-maximal effective concentration
Study
sheepn: not reported in source
primary pituitary cells
Comparator
GRF
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The half-maximal effective dose of KP 101 and GHRP-6 was 10(-7) M, an order of magnitude higher than that for GRF.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971702
03LabIn vitro (cells)Mechanism
In ovine pituitary cells, GHRP‑6 and KP 101 had similar maximal effects on GH release.
In plain wordsIn cells from sheep, GHRP‑6 and KP 101 had similar maximum effects on growth hormone release.
Peptide
GHRP-6
Outcome
No significant changeMaximal GH release versus KP 101
Study
sheepn: not reported in source
primary pituitary cells
Comparator
KP 101
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The maximal effects of KP 101 and GHRP-6 were similar but significantly less than the maximal effect of GRF.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971703
04LabIn vitro (cells)Mechanism
In ovine pituitary cells, GHRP‑6 had a significantly smaller maximal effect on GH release than GRF.
In plain wordsIn cells from sheep, GHRP‑6 released less growth hormone than GRF at maximum effect.
Peptide
GHRP-6
Outcome
DecreaseMaximal GH release versus GRF
Study
sheepn: not reported in source
primary pituitary cells
Comparator
GRF
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
The maximal effects of KP 101 and GHRP-6 were similar but significantly less than the maximal effect of GRF.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971704
05LabIn vitro (cells)Mechanism
In ovine pituitary cells, a second GHRP‑6 application after 1 h produced a lower response than the first.
In plain wordsIn cells from sheep, the second GHRP‑6 application released less growth hormone than the first.
Peptide
GHRP-6
Outcome
DecreaseRepeated application response
Study
sheepn: not reported in source
primary pituitary cells
Comparator
first application
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
For each peptide, the response to a second application (1 h after the first application) was lower than the first response.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971707
06LabIn vitro (cells)Mechanism
In ovine pituitary cells, adding GHRP‑6 to GRF produced only a small additive GH release effect at maximal doses.
In plain wordsIn cells from sheep, adding GHRP‑6 to GRF slightly increased growth hormone release at maximum doses.
Peptide
GHRP-6
Outcome
IncreaseAddition to GRF at maximal doses
Study
sheepn: not reported in source
primary pituitary cells
Comparator
GRF alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
Only a small additive effect on the release of GH by GRF was obtained by the co-administration of either KP 101 or GHRP-6.
2 context sentences(design, population, supporting numbers)
Summary · context
This result was achieved with maximal doses of the peptides, but not with half-maximal doses.(ABSTRACT TRUNCATED AT 250 WORDS)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971709
07LabIn vitro (cells)Mechanism
In ovine pituitary cells, adding GHRP‑6 to GRF did not produce the additive effect at half-maximal doses.
In plain wordsIn cells from sheep, adding GHRP‑6 to GRF did not produce the additive effect at half-maximal doses.
Peptide
GHRP-6
Outcome
No significant changeAddition to GRF at half-maximal doses
Study
sheepn: not reported in source
primary pituitary cells
Comparator
GRF alone
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
Dose not stated
Source sentences
Summary
This result was achieved with maximal doses of the peptides, but not with half-maximal doses.(ABSTRACT TRUNCATED AT 250 WORDS)
2 context sentences(design, population, supporting numbers)
Summary · context
Only a small additive effect on the release of GH by GRF was obtained by the co-administration of either KP 101 or GHRP-6.
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
Report a problemFND-0804971710

Studies that did not test the peptide alone3

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

08LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism
In ovine pituitary cells, calcium channel blockade completely and reversibly abolished GHRP‑6-induced GH release.
In plain wordsIn cells from sheep, calcium channel blockade stopped GHRP‑6-induced growth hormone release reversibly.
Peptide
GHRP-6
Outcome
DecreaseCalcium channel blockade
Study
sheepn: not reported in source
primary pituitary cells
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Blockade of calcium channels with Cd2+ (2 mM) totally and reversibly abolished the releasing effects of all three peptides.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0804971705
09LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism
In ovine pituitary cells, a GRF antagonist did not affect GHRP‑6-induced GH release.
In plain wordsIn cells from sheep, a GRF blocker did not change GHRP‑6-induced growth hormone release.
Peptide
GHRP-6
Outcome
No significant changeGRF antagonist effect
Study
sheepn: not reported in source
primary pituitary cells
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
Like GHRP-6, the GH release induced by KP 101 was not affected by a GRF antagonist ([Ac-Tyr1, D-Arg2]-GRF 1-29, 1 microM) which significantly reduced the effect of GRF on GH release.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0804971706
10LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism
In ovine pituitary cells, sequential exposure to different secretagogues did not attenuate the second response involving GHRP‑6.
In plain wordsIn cells from sheep, changing secretagogues did not reduce the second response involving GHRP‑6.
Peptide
GHRP-6
Outcome
No significant changeResponse after another secretagogue
Study
sheepn: not reported in source
primary pituitary cells
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
When GRF (or KP 101, GHRP-6) was applied first and then KP 101 or GHRP-6 (or GRF) given 1 h later, the second response was not attenuated.
1 context sentence(design, population, supporting numbers)
Summary · context
Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6).
In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.
Report a problemFND-0804971708

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
21 Oct 2026, 15:58 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.